Analysts Upgrade/Downgrade Activity of Ionis Pharmaceuticals, Inc. (IONS)

earnings estimates

Ionis Pharmaceuticals, Inc. (IONS) belonging to the Medical sector has surged 0.6% and closed its last trading session at $41.72.

The company reported its EPS on 02/28/2017. Currently, the stock has a 1 Year Price Target of $46.82.

The consensus recommendation, according to Zacks Investment research, is 2.5. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.

The Stock had a 2.5 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2.5 and 2.45 respectively.

Ionis Pharmaceuticals, Inc. on 02/28/2017 reported its EPS as $0.24 with the analysts projecting the EPS of the stock as $-0.12. The company beat the analyst EPS Estimate with the difference of $0.36. This shows a surprise factor of 300%.

Many analysts have provided their estimated foresights on Ionis Pharmaceuticals, Inc. Earnings, with 10 analysts believing the company would generate an Average Estimate of $0.04.

Whereas they predicted High and Low Earnings Estimate as $1.15 and $-0.56 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.52.

Analysts are also projecting an Average Revenue Estimate for Ionis Pharmaceuticals, Inc. as $115.58 Million in the Current Quarter. This estimate is provided by 11 analysts.

The High Revenue estimate is predicted as 276.87 Million, while the Low Revenue Estimate prediction stands at 57 Million. The company’s last year sales total was 36.87 Million.

For the Current Quarter, the growth estimate for Ionis Pharmaceuticals, Inc. is 107.7%, while for the Next Quarter the stock growth estimate is 27.7%.

The Company got Downgrade by Goldman on 10-Mar-17 from Neutral to Sell.

Insider Trades for Ionis Pharmaceuticals, Inc. show that the latest trade was made on 2 Mar 2017 where Bennett (C Frank), the Officer completed a transaction type “Buy” in which 5000 shares were traded at a price of $10.29.

11 analysts projected Price Targets for Ionis Pharmaceuticals, Inc.. The analysts believe that the company stock price could grow as high as $66. The Low Price target projection by analysts is $17 and the Mean Price Target is $46.82.

Ionis Pharmaceuticals, Inc. (IONS) has the market capitalization of $5.65 Billion. The company rocked its 52-Week High of $57 on Dec 27, 2016 and touched its 52-Week Low of $19.59 on May 27, 2016.

The stock has Return on Assets (ROA) of -10.1 percent. Return on Equity (ROE) stands at -68.1% and Return on Investment (ROI) of -7.7 percent.

The stock is currently showing YTD performance of -12.77 Percent. The company has Beta Value of 2.62 and ATR value of 2.67. The Weekly and Monthly Volatility stands at 5.84% and 5.38%.